Know Cancer

or
forgot password

Determining the Clinicopathological Significance of CaMKIIgamma Activation in AML


N/A
56 Years
N/A
Not Enrolling
Both
Leukemia

Thank you

Trial Information

Determining the Clinicopathological Significance of CaMKIIgamma Activation in AML


OBJECTIVES:

- Determine whether calmodulin-dependent protein kinase II-γ (CaMKIIγ) activation
(autophosphorylation) is associated with specific clinicopathological variables and
outcomes in blood and bone marrow samples from patients with previously untreated
primary acute myeloid leukemia.

OUTLINE: Blood and bone marrow samples are analyzed by western blot using SDS-PAGE and
immunoblotting using anti-calmodulin-dependent protein kinase II-γ (CaMKIIγ) and
anti-phosphospecific (Thr286, 287) CaMKIIγ antibodies with signals detected via
chemiluminescence. CaMKIIγ activation levels are linked to clinical variables within the
SWOG database.

Inclusion Criteria


DISEASE CHARACTERISTICS:

- Cryopreserved specimens of marrow or peripheral blood from patients enrolled in
clinical trial SWOG-9333 and meeting the following criteria:

- Diagnosis of primary acute myeloid leukemia

- No M3 disease

- Previously untreated disease

- Randomized to remission induction chemotherapy with mitoxantrone hydrochloride
and etoposide (Arm II)

PATIENT CHARACTERISTICS:

- Not specified

PRIOR CONCURRENT THERAPY:

- See Disease Characteristics

Type of Study:

Observational

Study Design:

Time Perspective: Retrospective

Outcome Measure:

Association of specific clinicopathological variables and outcomes with calmodulin-dependent protein kinase II-γ (CaMKIIγ) activation (autophosphorylation)

Outcome Time Frame:

upon receipt of specimens

Safety Issue:

No

Principal Investigator

Steven J. Collins, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Fred Hutchinson Cancer Research Center

Authority:

United States: Federal Government

Study ID:

CDR0000612640

NCT ID:

NCT00899743

Start Date:

August 2008

Completion Date:

June 2009

Related Keywords:

  • Leukemia
  • adult erythroleukemia (M6a)
  • adult pure erythroid leukemia (M6b)
  • adult acute megakaryoblastic leukemia (M7)
  • adult acute minimally differentiated myeloid leukemia (M0)
  • adult acute monoblastic leukemia (M5a)
  • adult acute monocytic leukemia (M5b)
  • adult acute myeloblastic leukemia with maturation (M2)
  • adult acute myeloblastic leukemia without maturation (M1)
  • adult acute myelomonocytic leukemia (M4)
  • adult acute myeloid leukemia with t(8;21)(q22;q22)
  • adult acute myeloid leukemia with t(16;16)(p13;q22)
  • adult acute myeloid leukemia with inv(16)(p13;q22)
  • adult acute myeloid leukemia with 11q23 (MLL) abnormalities
  • untreated adult acute myeloid leukemia
  • Leukemia
  • Leukemia, Myeloid, Acute
  • Leukemia, Myeloid

Name

Location